Patents Represented by Attorney, Agent or Law Firm Campbell & Flores LLP
-
Patent number: 6180084Abstract: The present invention provides a method of identifying a tumor homing molecule that homes to angiogenic vasculature by contacting a substantially purified NGR receptor with one or more molecules and determining specific binding of a molecule to the NGR receptor, where the presence of specific binding identifies the molecule as a tumor homing molecule that homes to angiogenic vasculature. The invention also provides a method of directing a moiety to angiogenic vasculature in a subject by administering to the subject a conjugate including a moiety linked to a tumor homing molecule that exhibits specific binding to an NGR receptor, whereby the moiety is directed to angiogenic vasculature. In addition, the invention provides a method of imaging the angiogenic vasculature of a tumor in a subject by administering to the subject a conjugate having a detectable moiety linked to a tumor homing molecule that exhibits specific binding to an NGR receptor and detecting the conjugate.Type: GrantFiled: August 25, 1998Date of Patent: January 30, 2001Assignee: The Burnham InstituteInventors: Erkki Ruoslahti, Renata Pasqualini
-
Patent number: 6177542Abstract: The present invention provides peptides having specificity for fibronectin-binding and vitronectin-binding integrins, and in particular for &agr;5&bgr;1 integrin. These peptides are characterized by having the ability to interfere with extracellular matrix protein binding to integrins; to block attachment of cells expressing these integrins to extracellular matrix proteins; and to promote cell attachment when coated onto a surface.Type: GrantFiled: August 29, 1997Date of Patent: January 23, 2001Assignee: The Burnham InstituteInventors: Erkki Ruoslahti, Erkki Koivunen
-
Patent number: 6174687Abstract: The present invention provides a method of identifying a membrane dipeptidase (MDP)-binding homing molecule that selectively homes to lung endothelium. The method includes the steps of contacting MDP with one or more molecules; and determining specific binding of a molecule to the MDP, where the presence of specific binding identifies the molecule as a MDP-binding homing molecule that selectively homes to lung endothelium. Such MDP-binding homing molecules can be linked to a moiety and, when administered to a subject as a conjugate, can selectively direct the moiety to lung endothelium in the subject.Type: GrantFiled: February 26, 1999Date of Patent: January 16, 2001Assignee: The Burnham InstituteInventors: Daniel Rajotte, Renata Pasqualini, Erkki Ruoslahti
-
Patent number: 6172187Abstract: The present invention provides a mammalian CD40-associated protein (CAP), a nucleic acid molecule encoding the CAP and antibodies specific for the CAP. The invention further provides a substantially purified human CAP-1 and a nucleic acid molecule encoding human CAP-1. The invention also provides screening assays for identifying an agent that effectively alters the association of a CAP with a second molecule, which can bind to the CAP. In addition, the invention provides methods for identify a CAP agonist or CAP antagonist that can increase or decrease, respectively, the level of expression of the CAP in a cell. Such an effective agent, agonist or antagonist can modulate a function of a cell such as a humoral immune response or cell growth. The invention also provides methods of detecting a CAP in a sample by detecting the CAP or a nucleic acid molecule encoding the CAP. Such methods can be used to diagnose a pathology that is characterized by an increased or decreased level of a CAP in a cell.Type: GrantFiled: August 27, 1996Date of Patent: January 9, 2001Assignee: La Jolla Cancer Research FoundationInventors: John C. Reed, Takaaki Sato
-
Patent number: 6159470Abstract: The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the mammal in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides a specific .beta.-chain variable region of the T cell receptor, designated V.beta.17, which is central to the pathogenesis of rheumatoid arthritis (RA).Type: GrantFiled: June 5, 1995Date of Patent: December 12, 2000Assignee: The Immune Response CorporationInventors: Mark D. Howell, Steven W. Brostoff, Dennis J. Carlo
-
Patent number: 6146623Abstract: A composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% human myeloblasts and promyelocytes, which have been derived from neutrophil progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5% colony forming units (CFU) of at least about 50 cells is provided. An alternative composition comprising genetically altered human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CD11b- cells and less than about 5% colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60% of the CD15+CD11b- cells are myeloblasts and promyelocytes.Type: GrantFiled: June 7, 1995Date of Patent: November 14, 2000Assignee: Nexell Therapeutics Inc.Inventors: James G. Bender, Phillip B. Maples, Stephen Smith, Kristen L. Unverzagt, Dennis E. Van Epps
-
Patent number: 6143895Abstract: The present invention relates to novel tetrahydro-quinoline compounds of the following formula, libraries containing such compounds, and to the generation of such combinatorial libraries composed of such compounds: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and Y have the meanings provided.Type: GrantFiled: August 20, 1998Date of Patent: November 7, 2000Assignee: Trega Biosciences, Inc.Inventors: Yazhong Pei, John S. Kiely
-
Patent number: 6143932Abstract: The instant invention is directed to a single, selectively N-alkylated compound and libraries of such compounds as set forth in Formula I. Furthermore, the instant invention is directed to methods of effecting analgesia, a decrease in the postprandial rise in the blood glucose levels of a mammal after ingestion of a carbohydrate load by said mammal, and treating microbial infections, utilizing such a single compound of Formula I in conjunction with a pharmaceutically-acceptable carrier. Also, the instant invention is directed to methods for selective alkylation, positional scanning and iterative synthetic and screening technologies.Type: GrantFiled: July 1, 1999Date of Patent: November 7, 2000Assignee: Trega Biosciences, Inc.Inventors: Barbara Dorner, John M. Ostresh, Colette T. Dooley, Richard A. Houghten, Jutta Eichler
-
Patent number: 6140136Abstract: The present invention provides an analytical test device for conducting assays of biological fluids. Methods for carrying out the assays with the disclosed analytical test device are also provided.Type: GrantFiled: September 18, 1998Date of Patent: October 31, 2000Assignee: Syntron BioResearch, Inc.Inventor: Jin Po Lee
-
Patent number: 6136580Abstract: The present invention provides a substantially pure C2GnT-M polypeptide or a functional fragment or derivative thereof, wherein C2GnT-M is characterized as a polypeptide having core 2, core 4 and I branching .beta.-1.fwdarw.6-N-acetylglucosaminyltransferase activities. The invention also provides a substantially pure C2GnT-M peptide, wherein the peptide is immunogenic. Also provided is a method of modifying an acceptor molecule by contacting the acceptor molecule with a substantially pure C2GnT-M polypeptide or a functional fragment under conditions that allow addition of core 2, core 4 or I GlcNAc linkages to the acceptor molecule, and an acceptor molecule produced by the method. Also provided is a substantially pure nucleic acid molecule having substantially the nucleic acid sequence designated SEQ ID NO: 1, or the complement thereof.Type: GrantFiled: January 19, 1999Date of Patent: October 24, 2000Assignee: The Burnham InstituteInventors: Minoru Fukuda, Jiunn-Chern Yeh
-
Patent number: 6136952Abstract: The present invention provides an isolated polypeptide exhibiting substantially the same amino acid sequence as JAGGED, or an active fragment thereof, provided that the polypeptide does not have the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6. The invention further provides an isolated nucleic acid molecule containing a nucleotide sequence encoding substantially the same amino acid sequence as JAGGED, or an active fragment thereof, provided that the nucleotide sequence does not encode the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6. Also provided herein is a method of inhibiting differentiation of hematopoietic progenitor cells by contacting the progenitor cells with an isolated JAGGED polypeptide, or active fragment thereof. The invention additionally provides a method of diagnosing Alagille Syndrome in an individual. The method consists of detecting an Alagille Syndrome disease-associated mutation linked to a JAGGED locus.Type: GrantFiled: June 25, 1997Date of Patent: October 24, 2000Assignee: University of WashingtonInventors: Linheng Li, Leroy Hood
-
Patent number: 6133503Abstract: The present invention provides a mammalian artificial chromosome (MAC), comprising a centromere and a unique cloning site, said MAC containing less than 0.1% of the DNA present in a normal haploid genome of the mammalian cell from which the centromere was obtained. The invention further provides a MAC, wherein the unique cloning site is a nucleic acid sequence encoding a selectable marker. The invention also provides methods of preparing a MAC. In addition, the invention provides methods of stably expressing a selectable marker in a cell, comprising introducing a MAC containing the selectable marker into the cell. The invention also provides a cell containing a MAC expressing an exogenous nucleic acid sequence and a transgenic mammal expressing a selectable marker.Type: GrantFiled: February 17, 1998Date of Patent: October 17, 2000Assignee: The Regents of the University of CaliforniaInventor: Immo E. Scheffler
-
Patent number: 6132989Abstract: The invention provides compositions of a non-adenoviral vector containing a polynucleotide sequence encoding adenoviral pTP operationally linked domain. The invention also provides compositions of an adenoviral pTP binding domain. The invention also provides methods for increasing the expression of a polynucleotide by expressing the polynucleotide in a non-adenoviral vector containing an adenoviral pTP binding domain in the presence of adenoviral pTP. The invention additionally provides methods to increase expression of a heterologous polynucleotide in an individual by obtaining cells from the individual, genetically altering the cells to express a non-adenoviral vector containing an adenoviral pTP binding domain and a gene encoding pTP and readministering the genetically altered cells to the individual.Type: GrantFiled: November 18, 1997Date of Patent: October 17, 2000Assignee: University of WashingtonInventors: Mark A. Kay, Andre Lieber
-
Patent number: 6130317Abstract: The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid molecules complementary thereto (SEQ ID NO: 2 and SEQ ID NO: 5, respectively), portions of such nucleic acid molecules, vectors containing the nucleic acid molecules, and host cells containing the vectors. The invention also provides methods of using such nucleic acid molecules to identify the presence of a nucleic acid molecule encoding a Bax inhibitor protein in a sample or to increase or decrease the level of expression of a Bax inhibitor protein in a cell. In addition, the invention provides substantially purified BI-1 (SEQ ID NO: 3) and BI-2 (SEQ ID NO: 6) polypeptides, portions of such polypeptides, and antibodies specific for BI-1 or BI-2.Type: GrantFiled: July 15, 1998Date of Patent: October 10, 2000Assignee: The Burnham InstituteInventors: John C. Reed, Qunli Xu
-
Patent number: 6127381Abstract: The invention relates to melanocortin receptor ligands and methods of using the ligands to alter or regulate the activity of a melanocortin receptor. The invention further relates to tetrahydroisoquinoline aromatic amines that function as melanocortin receptor ligands and as agents for controlling cytokine-regulated physiologic processes and pathologies, and combinatorial libraries thereof.Type: GrantFiled: April 28, 1999Date of Patent: October 3, 2000Inventors: Amaresh Basu, Timothy C. Gahman, Beverly E. Girten, Michael C. Griffith, Curtis C. Hecht, John S. Kiely, Sandra R. Slivka
-
Patent number: 6127123Abstract: The present invention provides a nucleic acid molecule encoding a CAULIFLOWER (CAL) gene product such as a nucleic acid molecule encoding Arabidopsis thaliana CAL and a nucleic acid molecule encoding Brassica oleracea CAL (BoCAL). The invention also provides a nucleic acid molecule encoding a truncated CAL gene product such as a nucleic acid molecule encoding Brassica oleracea var. botrytis CAL (BobCAL). The invention also provides a nucleic acid containing the Arabidopsis thaliana CAL gene, a nucleic acid molecule containing the Brassica oleracea CAL gene and a nucleic acid molecule containing the Brassica oleracea var. botrytis CAL gene. The invention further provides a kit for converting shoot meristem to floral meristem and a kit for promoting early flowering in an angiosperm. The invention provides a CAL polypeptide and an antibody that specifically binds CAL polypeptide.Type: GrantFiled: September 9, 1998Date of Patent: October 3, 2000Assignee: Regents of the University of CaliforniaInventor: Martin F. Yanofsky
-
Patent number: 6121489Abstract: The instant invention is directed to a single, selectively N-alkylated compound and libraries of such compounds as set forth in Formula I. Furthermore, the instant invention is directed to methods of effecting analgesia, a decrease in the postprandial rise in the blood glucose levels of a mammal after ingestion of a carbohydrate load by said mammal, and treating microbial infections, utilizing such a single compound of Formula I in conjunction with a pharmaceutically-acceptable carrier. Also, the instant invention is directed to methods for selective alkylation, positional scanning and iterative synthetic and screening technologies.Type: GrantFiled: March 5, 1997Date of Patent: September 19, 2000Assignee: Trega Biosciences, Inc.Inventors: Barbara Dorner, John M. Ostresh, Colette T. Dooley, Richard A. Houghten, Jutta Eichler
-
Patent number: 6120763Abstract: The invention provides a method of preventing or reducing the severity of a cancer in a subject by stimulating the subject's immune response against the cancer. The invention provides, for example, a method of stimulating an immune response in a subject by administering to the subject tumor cells that are substantially similar to the subject's cancer cells and that are genetically modified to reduce or inhibit the expression of one or more immunosuppressive agents. The invention also provides a method of preventing or reducing the severity of cancer in a subject by stimulating the subject's immune response against the cancer by administering to the subject tumor cells that are substantially similar to the subject's cancer cells and that are genetically modified to prevent the expression of an immunosuppressive agents and, in combination with the genetically modified tumor cells, an immunostimulatory agent. The invention further provides compositions useful for practicing the claimed methods.Type: GrantFiled: November 12, 1997Date of Patent: September 19, 2000Assignee: Sidney Kimmel Cancer CenterInventors: Habib Fakhrai, Oliver Dorigo, Robert E. Sobol
-
Patent number: 6117840Abstract: The present invention contemplates a peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory peptide are also disclosed.Type: GrantFiled: April 14, 1997Date of Patent: September 12, 2000Assignee: Cytel CorporationInventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
-
Patent number: 6113903Abstract: This invention relates to methods of preventing or reducing the severity of diabetes. In one embodiment, the method involves administering to the individual a peptide having substantially the sequence of a on-conserved region sequence of a T cell receptor present on the surface of T cells mediating diabetes or a fragment thereof, wherein the peptide or fragment is capable of causing an effect on the immune system to regulate the T cells. In particular, the T cell receptor has the V.beta. regional V.beta.6 or V.beta.14. In another embodiment, the method involves gene therapy. The invention also relates to methods of diagnosing diabetes by determining the presence of diabetes predominant T cell receptors.Type: GrantFiled: February 14, 1994Date of Patent: September 5, 2000Assignee: The Immune Response CorporationInventors: Richard J. Albertini, Michael T. Falta